Sangrail Debuts as New Biotech, Picks Up Dropped Gene Therapy for Sanfilippo Syndrome Type B

Sangrail Biologics launched as a new biotech to advance SNG-101, a gene therapy for Sanfilippo syndrome type B, reviving the program after its discontinuation by Abeona Therapeutics. SNG-101 showed promising Phase I/II clinical trial results with dose-dependent enzyme activity increases and reduced disease burden, with Sangrail engaging FDA and other regulators for next steps.

This Wire brief sits within Fusion42's coverage of Biotech.